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Radionuclide therapy for cancer is undergoing a renaissance, with a wide range of radionu-
clide and clinical delivery systems currently under investigation. Dosimetry at the cellular
and sub-cellular level is complex with inhomogeneity and incomplete targeting of all cells
such that some tumor cells will receive little or no direct radiation energy. There is now
sufficient preclinical evidence of a Bystander response which can modulate the biology of
these un-irradiated cells with current research demonstrating both protective and inhibitory
responses. Dependence upon fraction of irradiated cells has also been found and the pres-
ence of functional gap junctions appears to be import for several Bystander responses.The
selection of either high or low LET radionuclides may be critical. While low LET radionu-
clides appear to have a Bystander response proportional to dose, the dose-response from
high LET radionuclides are more complex. In media transfer experiments a “U” shaped
response curve has been demonstrated for high LET treatments. However this “U” shaped
response has not been seen with co-culture experiments and its relevance remains uncer-
tain. For high LET treatments there is a suggestion that dose rate effects may also be
important with inhibitory effects noted with 125I labelling study and a stimulatory seen
with 123I labelling in one study.
Keywords: radionuclide, radioisotope, Bystander effect, targeted alpha therapy, targeted radionuclide therapy,
radiopharmaceuticals
INTRODUCTION
The concept that ionizing radiation can have a biological effect
upon cells which receive no direct energy deposition is now well
established. Blyth and Sykes, in a recent review,have sought to stan-
dardize the definition of this Bystander response as “Radiation-
induced, signal-mediated effects in un-irradiated cells within
an irradiated volume” (1). These signal mediated Bystander
effects include cell death, DNA damage, chromatid aberrations,
genomic instability, transformation, differentiation, proliferation,
gene expression, cell cycle, invasion, and radioadaptive responses.
Release of signaling molecules (2) and direct intercellular com-
munication via gap junctions are the two primary mechanisms
involved (3). Cell proximity has also shown to be necessary for
proliferative Bystander responses (4). Reactive oxygen and nitro-
gen species together with calcium and cytokines have all been
implicated in Bystander signaling [see Ref. (5) a review]. Much of
the evidence for Bystander response is drawn from experiments
with external radiation sources with comparatively fewer reports
involving radionuclides.
Clinically radionuclides have demonstrated utility in med-
ical imaging technologies and therapeutic treatments. Radioio-
dine therapy with Na131I is well established in the treatment
of differentiated thyroid cancer (6). In the treatment of lym-
phoma two radioimmunotherapies are commercially available
90Y-ibritumomab tiuxetan and 131I-tositumomab, both are radi-
olabeled anti-CD20 antibodies (7, 8). For the palliation of
bone metastasis there are several therapies in use, 89Sr, 153Sm,
186Re, 188Re, 223Ra (9). Radioembolisation with 90Y micros-
pheres has been used for the treatment of hepatocellular car-
cinoma. 131I-MIBG is indicated in the treatment of pheochro-
mocytoma, paraganglioma, carcinoid tumor, neuroblastoma, and
medullary thyroid cancer (10). Peptide receptor therapy with 90Y-
DOTATATE/90Y-DOTATOC is used for the treatment of metastatic
neuroendocrine tumors (11). In addition there are many more
radionuclides undergoing clinical trials. There is now, however, a
renewed interest in radionuclide therapy with the results of the
recent ALSYMPCA trial demonstrating a survival advantage for
the use of 223Ra in the treatment of prostate cancer bone metastasis
(12) and the subsequent FDA approval of this radiopharmaceuti-
cal. The non-uniform dose deposition from radionuclide therapy
and the inability to target all tumor cells provides a potential niche
for Bystander responses to have a significant impact in this setting.
DOSIMETRIC CONSIDERATIONS
In clinical radiation therapy there are important dosimetric differ-
ences between external beam or sealed source brachytherapy and
unsealed radionuclide therapy. Linear accelerator based external
beam radiotherapy (EBRT) uses high energy photons (4–18 MeV)
to flood a target volume, irradiating all cells within the field,
including both tumor and normal tissue in the treatment field.
Furthermore the total dose of EBRT is often fractionated over
several weeks with each fraction typically delivered over several
minutes. This is in sharp contrast to radionuclide therapy, which
attempts to molecularly target dose in a tissue specific, as opposed
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to a volume specific, manner. The rate of dose delivery to a tumor
is complex depending upon the specific activity and half-life of
the radionuclide, its radiation properties (radiation types, ener-
gies, and yields), and absorption into the tumor mass, combined
with the biological transit time and clearance. At a macroscopic
level the dose delivered from a radionuclide appears uniform,
however at the cellular and sub-cellular levels there is actually
significant inhomogeneity. Many cells will not be affected directly
by the radiation and the energy deposition will consist of multi-
ple hotspots. With such non-uniform radionuclide exposures the
mean absorbed dose is not the best parameter to predict biologi-
cal response (13). Classically radionuclides have been chosen with
radiation decay path lengths long enough to compensate for the
incomplete targeting of all tumor cells but short enough to reduce
the dose to surrounding normal tissue. Samarium-153 EDTMP
(153Sm) is often used in the treatment of bone metastasis, as the
effective range of its beta emission is 2–3 mm. This is long enough
to deliver a dose to the adjacent tumor tissue but short enough
to minimize the dose to the radiosensitive normal bone marrow.
Those cells which are not directly targeted may then still receive
a dose from the crossfire emanating from a neighboring targeted
cell. It is in this population of cells which are un-irradiated or only
sparsely irradiated by crossfire that the impact of the Bystander
effect may be crucial in order to achieve sterilization of a tumor as
a whole (see Figure 1). Historically the radionuclides for therapeu-
tic use were therefore typically low LET beta emitters. Recently this
paradigm has been challenged with radionuclides such as Radium-
223 (223Ra), a high linear energy transfer (LET) alpha emitter with
a short range, less than 100µm (12).
To achieve selective tissue uptake there are several strategies to
deliver radionuclides. The radionuclide can be administered as a
radioactive salt such as 89Sr or 233Ra both of which are calcium
FIGURE 1 | (A) Isolated radiation crossfire model, the biological effect to
un-irradiated cells is related to the path length of the radionuclide. (B)
Bystander and crossfire model, additional non-targeted cells receive a
biological effect from Bystander signaling.
mimetics and can therefore be absorbed by the dysregulated bone
at the sites of skeletal metastasis. Radioiodine therapy for the
treatment of thyroid cancer is also unique, as the sodium/iodide
symporter predominates within thyroid tissue and selective uptake
of the radionuclide is easily achieved. Such convenience is uncom-
mon and many of the clinically available radionuclides require
a carrier molecule to localize to the tissue of interest. Bisphos-
phonates can be used to localize to bone (186Re, 188Re, 153Sm) or
a radioimmunotherapy approach with monoclonal antibody to
epitopes such as CD20 found on malignant B lymphocytes (e.g.,
Ibritumomab tiuxetan 90Y). Radiohalogens can be incorporated
into molecules such as MIBG (131I, 123I) enabling internalization
into cells which express the NAT receptor such as neural crest can-
cers (14). Irrespective of the specificity of targeting, normal tissue
often still receives a radiation dose either from crossfire in a tumor
adjacent area or to the organs involved in transport and excretion
of the radionuclide.
EXPERIMENTAL EVIDENCE FOR BYSTANDER RESPONSE
WITH RADIONUCLIDES
IN VITRO
In vitro experiments to investigate the Bystander response in
radionuclide therapy are more challenging than external beam
experiments. There are practical issues such as ensuring there
is a population of un-irradiated cells, with no radionuclide
incorporation. Several studies have demonstrated a Bystander
response using 3H (tritium) as a short range beta emitter incorpo-
rated into the DNA with thymidine (3H-dThd). 3H decays releas-
ing low LET beta particles with a mean energy of 5.67 keV and a
very short range of only 1µm, effectively restricting the radiation
dose to within the cell, with no extracellular crossfire. Early evi-
dence of a Bystander response was demonstrated by Bishayee et al.
(15) using Chinese hamster V79 cells labeled with 3H-dThd. These
cells were mixed with varying concentrations of unlabeled cells
centrifuged into multicellular clusters of about 1.6 mm in diameter
and plated for a colony survival assay after 72 h. At 100% labeling of
cells in the cluster colony survival depended exponentially on clus-
ter activity. At 50% of cell labeling colony survival was lower than
predicted and this was attributed to a Bystander response. Addi-
tion of the gap junction inhibitor lindane had no effect on colony
survival for the 100% labeled cells but colony survival increased
with dose up to a plateau for the 50% labeled cells, suggesting a
role for intracellular communication in this Bystander response.
Further experiments with a lower 10% labeling of cells confirmed
the protective effect with lindane and also to a lesser extent the
radical scavenger DMSO (16). In additional experiments utiliz-
ing 125I labeled iododeoxyuridine (125IUdR) incorporated into
DNA, they labeled 100, 50, and 10% of V79 cells in a multicellu-
lar cluster. 125I emits predominantly Auger electrons (low energy
conversion electrons and gamma rays are also emitted) depositing
99% of the dose within 0.5µm with little extracellular crossfire.
These clusters were then disaggregated and plated for colony sur-
vival. Survival of the cells in the 50 and 10% labeling groups was
lower than predicted from dosimetric estimations (17). The same
group performed co-culture of 3H-dThd labeled rat epithelial cells
(WB-F344) with unlabeled cells. They used a fluorescent stain-
ing approach to discriminate the two cell populations by flow
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cytometry with the membrane permeant reactive tracer, carboxy-
fluorescein diacetate succinimidyl ester (CFDA SE). Co-culturing
of labeled and unlabeled cells led to an increase in the prolifer-
ation of Bystander cells. This increase in proliferation ratios was
dependent on the fraction of labeled cells present (18, 19). Per-
saud et al. labeled CHO cells with 3H-dThd and co-cultured these
with unlabeled AL cells in a 1:5 ratio to produce a multicellular
spheroid of cells. The AL cells were separated with magnetic beads
and mutation analysis performed. Increased rates of mutations
were found in the un-irradiated AL cells together with decreased
clonogenic survival. As with the previous studies the addition of
lindane or DMSO was found to abrogate the mutation frequency.
They similarly demonstrated a role for reactive oxygen species and
gap junction intercellular communication (20, 21). Chouin and
Bernardeau labeled antibodies with 213Bi to target two lymphoid
cell lines in vitro. 213Bi is predominately a beta emitter (98% beta
decay, 2% alpha decay) with a short path length of 50µm (22). At
low mean absorbed doses, cell mortality was higher than expected
from modeling the probability of a radiation cell hit, suggestive
of a Bystander response. Indeed it’s likely that the alpha decay of
210Po, a daughter product of 213Bi is responsible for this low dose
effect. Howell et al. observed a similar phenomenon utilizing their
V79 multicellular cluster model labeling with 210Po (23). At 1%
labeling of cells a decrease in predicted clonogenic survival was
noted.
Targeting normal tissue with the expectation that Bystander
signaling will cause cell kill in an adjacent tumor population
has many potential advantages. Mamlouk et al. labeled human
lymphocytes with 125I labeled iododeoxyuridine (125IUdR) and
co-cultured them with the colon adenocarcinoma cell line LS174T
in vitro. There was decreased survival seen with the LS174T cells
both in direct co-culture and with a media transfer experiment
(24). To demonstrate that the Bystander response was not in fact
due to crossfire from the radionuclide decay in a separate exper-
iment the labeled cells were killed and then incubated resulting
in the abrogation of the previously observed Bystander response.
Akududu et al. employed a 3D carbon scaffold culture method
to investigate Bystander responses in two breast cancer cell lines
MCF-7 and MDA-MB-231. The cultures were pulse labeled with
125IUdR and 5-ethynyl-2′-deoxyuridine (EdU) to identify labeled
cells by flow cytometry (25). 15% of the MCF-7 cells were labeled
and 10% of the MDA cells, yet a lethal Bystander effect was only
observed in the MDA-MB-231 cells.
IN VIVO
Bystander responses have been demonstrated in several in vivo
models. Xue et al. used a protocol injecting human colon LS174T
adenocarcinoma cells into nude mice (26). LS174T cells were
labeled with 125IUdR then mixed with unlabeled cells and dead
cells (produced by freeze thawing and used as cell spacers). The
labeled cells incorporated a lethal dose, the estimated dose received
by the unlabeled cells was less than 10 cGy and the dead cells
were used as spacers to ensure consistent spacing of labeled
and unlabeled cells. Any delay in tumor growth could therefore
be attributed to the effects on the unlabeled cells. The group
observed inhibition of tumor growth at 1:1 and 1:5 labeling
ratios. Metaiodobenzylguanidine (MIBG) is a molecule similar
in structure to noradrenaline and as such is transported intracel-
lularly via the Noradrenaline Transport (NAT) receptor. Neural
crest tumors express this receptor and can be targeted with labeled
MIBG. Clinically MIBG can be labeled with 123I (utilizing the
gamma decay component) for imaging studies or the beta emitter
131I for therapeutic use. Transfection of other tumor types with
the NAT gene has been explored as a potential mechanism to target
radionuclide therapy within model systems. Several authors have
utilized this system with 131I-MIBG to partially irradiate trans-
genic mosaic xenograft models with varying ratios of tumor cells
expressing the NAT gene. While a reduction in tumor growth has
been noted, beyond what would be expected from the fraction
directly irradiated it’s unclear the relative proportion of cells kills
by crossfire vs. a biologic Bystander effect (27–29).
FACTORS THAT MIGHT AFFECT RADIONUCLIDE BYSTANDER
RESPONSE
THE INFLUENCE OF LET
Micrometasis represent a challenge to deliver radionuclides at a
concentration sufficient to sterilize a small volume of cells. In this
scenario High LET radiation such as alpha particles have a theo-
retical advantage over the low LET particles used for many clinical
treatments. It is estimated that between 100 and 1000 beta particle
traversals are required to kill a cell, compared to between 1 and
10 alpha particle traversals (30). The probability of a beta particle
inflicting a lethal lesion is therefore small at low fluences. Alpha
particles however demonstrate a log-linear cell kill even at low
doses, with a greater relative cell kill at low doses, compared to low
LET radiation. In acknowledgment of these differences the term
Targeted Alpha Therapy has been used to describe the clinical use
of alpha emitting radionuclides. Boyd et al. investigated the rela-
tionship between LET and Bystander response from media transfer
clonogenic experiments. Two tumor cell lines were transfected
with the NAT gene and exposed to either 123I-MIBG, 131I-MIBG,
211At-MABG, or external gamma rays. Consistent with previous
external beam Bystander studies the media from the externally
irradiated cells caused a Bystander response at low doses, satu-
rating with a maximum cell kill of 30–40% and no additional
effect beyond this plateau despite higher doses. In contrast no such
saturation of Bystander response was seen for the radionuclides.
Following treatment with the low LET beta emitter 131I-MIBG a
Bystander response was observed which increased in proportion to
the activity added to the directly exposed cells, leading to the killing
of 70–80% of the Bystander cells. The high LET emitting radionu-
clides 123I-MIBG and 211At-MAGB demonstrated an increasing
cell kill at lower doses up to a maximum of 35–70% then the effect
became less with increasing activities. This lead to a U-shaped
response curve,with a high Bystander response at low activities and
a lower Bystander response at higher activities. Boyd et al. investi-
gated the relationship between LET and sub-cellular location using
131I (a low LET beta emitter), and 123I (a high LET Auger electron
emitter) to label either MIBG (accumulates within the cytoplasm)
or IUdR (incorporates into DNA). They irradiated HCT116 cells
transformed with the NAT gene and performed media transfer to
test for a Bystander response. Treatment of the cells with the low
LET 131I caused a dose dependant decrease in clonogenic survival
for both the MIGB and the IUdR experiments. However the high
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LET 123I treatment demonstrated a U-shaped response to both
IUdR and MIBG treatments. Clonogenic survival decreased as the
dose increased to a maximum effect at 4 MBq mL1 after which
at higher doses the effect became proportionally less. They con-
cluded that radiopharmaceutical-induced Bystander effects may
depend on LET of the decay particles but are independent of
the site of intracellular concentration of the radionuclide (31).
Paillas et al. demonstrated a Bystander response in a media trans-
fer experiment with 125I labeled monoclonal antibodies targeting
CEA (non-internalizing, membrane destined) and HER2 (inter-
nalizing, cytoplasm destined) on HCT116 cells (32). Increased
numbers of gamma-H2AX foci, indicative of double strand DNA
breaks, were observed in recipient cells incubated in media from
both the CEA and HER2 exposed populations suggesting that high
LET Auger electrons can induce a Bystander response from both
membrane and cytoplasmic targeting. It also confirms microbeam
studies indicating sensitive sites for radiation exposure outside the
cell nucleus impacting on both direct (33) and Bystander responses
(34). Kishikawa et al. compared the effects of two high LET labeling
strategies with 123I and 125I in an in vivo model. They reported two
opposing effects, an inhibitory response for the 125I labeled study
and a stimulatory response for 123I labeled study. These observa-
tions were also confirmed in vitro. While both 123I and 125I have
similar emission spectra there are marked differences in radionu-
clide half-life (123I t 1/2 = 13.3 h and 125I t 1/2 = 60.5 days). For this
high LET model dose rate effects may therefore be important (35).
CLINICAL RELEVANCE
Investigation of a Bystander response within a clinical setting
would be exceptionally challenging. For both external beam and
radionuclide approaches, any Bystander response will be in addi-
tion to the direct effects of radiation exposure. It is likely that
designing a clinical trial to specifically test the extent of an effect
could only be done under conditions were a complimentary mol-
ecularly targeted approach to either enhance tumor cell kill or
protect normal tissue by Bystander signaling would be feasible.
There is renewed interest in radionuclide therapies, once seen
as a palliative tool for bone metastasis or treating rare tumors
such as thyroid cancer, they are now being investigated for a large
variety of tumor types. The basic principle that not all tumor
cells can be targeted remains, however what has changed is our
approach to those untargeted cells. Together with the radiation
crossfire effect, the contribution of Bystander signaling must also
be considered. Incorporation of a Bystander effects model could
have profound implications on the modern design and clinical
delivery of such radionuclides. Understanding Bystander signal-
ing mechanisms may allow us to more optimally target tumors
and protect surrounding normal tissues (5). The relative contri-
butions of radiation crossfire and Bystander effect are particularly
important to many of the clinically available therapies. The ratio
of cells that need to be targeted to achieve a Bystander effect is
also important; establishing thresholds for Bystander activation
may set the bar for a therapeutic benefit. It is likely that individual
tumor characteristics are important as demonstrated by the pres-
ence and absence of Bystander responses in two different breast
cancer cell lines (25). Indeed whether this response is protective
(advantageous for normal tissue) or inhibitory (advantageous for
tumor sterilization) needs to be established for each radionuclide,
delivery system, dose, and tumor combination. The mechanism of
the Bystander effect for high LET therapies also requires further
investigation, with some ex vivo evidence suggesting a favorable
dose at which maximum Bystander effect is achieved; which if
true in vivo has important implications for the fractionation and
dosing of such treatments.
There are important implications for clinical imaging technolo-
gies utilizing 123I such as 123I-MIBG which decays by electron
capture with Auger electron emission but clinically the small
gamma component is utilized to image tumors deep within a
patient. Previously it was thought that any direct DNA damage
would be small, caused by a few higher energy Auger electrons
or conversion electrons with most of the Auger electrons of such
short range to be of no threat to the nucleus. The Bystander effects
observed from such decays suggest that an indirect mechanism can
cause DNA damage which could result in an underestimation of
secondary cancer risk from the Linear no Threshold model (36).
Modulation of these Bystander responses will also be a therapeu-
tic goal. Quenching it may, in theory at least, reduce the risk of
secondary cancers, while enhancing the Bystander response could
result in therapeutic gain for cancer treatment.
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